<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02379910</url>
  </required_header>
  <id_info>
    <org_study_id>1030-260-01</org_study_id>
    <secondary_id>2014-003684-38</secondary_id>
    <nct_id>NCT02379910</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Tolerability, PK and PD of AM1030-CREAM in Patients With Atopic Dermatitis</brief_title>
  <official_title>AM1030: A Phase I/II, Double-Blind, Placebo-Controlled, Single and Multiple Ascending (Topical) Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Patients (Male and Female) With Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AnaMar AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Covance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AnaMar AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of safety, tolerability, pharmacokinetics and pharmacodynamics of
      AM1030-CREAM in patients with Atopic Dermatitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Day 1-15</time_frame>
    <description>Number of adverse events as a measure of Safety</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local Tolerability: Change in Erythema (Likert scale 0-4)</measure>
    <time_frame>Day 1-15</time_frame>
    <description>Change in Erythema (Likert scale 0-4) as a measure of Local Tolerability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local Tolerability: Change in Oedema (Likert scale 0-3)</measure>
    <time_frame>Day 1-15</time_frame>
    <description>Change in Oedema (Likert scale 0-3) as a measure of Local Tolerability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local Tolerability: Change in Burning (Likert scale 0-3)</measure>
    <time_frame>Day 1-15</time_frame>
    <description>Change in Burning (Likert scale 0-3) as a measure of Local Tolerability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local Tolerability: Change in Prutitus (VAS)</measure>
    <time_frame>Day 1-15</time_frame>
    <description>Change in Prutitus (VAS) as a measure of Local Tolerability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>Day 1-15</time_frame>
    <description>Change in blood pressure as a measure of Safety</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>Day 1-15</time_frame>
    <description>Change in pulse rate as a measure of Safety</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>Day 1-15</time_frame>
    <description>Change in body temperature as a measure of Safety</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG</measure>
    <time_frame>Day 1-15</time_frame>
    <description>Change in ECG as a measure of Safety</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical Examination</measure>
    <time_frame>Day 1-15</time_frame>
    <description>Any abnormal observations from Physical Examination as a measure of Safety</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Cmax, AUC, tmax, t1/2, Vss/F, CL/F</measure>
    <time_frame>Profil Day 1-15</time_frame>
    <description>Pharmacokinetics as measured by Cmax, AUC, tmax, t1/2, Vss/F, CL/F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pruritus on a Visual Analog Scale</measure>
    <time_frame>Day 1-15</time_frame>
    <description>Pruritus (Visual Analog Scale 10 cm) as a measure of Efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythema on a Likert scale</measure>
    <time_frame>Day 1-15</time_frame>
    <description>Erythema (Likert Scale 0-4) as a measure of Efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Eczema Area and Severity Index (mEASI)</measure>
    <time_frame>Day 1-15</time_frame>
    <description>mEASI (Composite score 0-64.8) as a measure of Efficay</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>SAD 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM1030-CREAM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM1030-CREAM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM1030-CREAM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM1030-CREAM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM1030-CREAM</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AM1030-CREAM or placebo</intervention_name>
    <arm_group_label>SAD 1</arm_group_label>
    <arm_group_label>SAD 2</arm_group_label>
    <arm_group_label>SAD 3</arm_group_label>
    <arm_group_label>MAD 1</arm_group_label>
    <arm_group_label>MAD 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and/or females of any ethnic origin between 18 and 65 years of age

          -  Body mass index between 18.0 and 35.0 kg/m2

          -  Subjects with AD as defined by the Hanifen and Rajka criteria and with mild to severe
             disease activity (IGA 2-4)

          -  AD lesions amenable to cutaneous treatment located on the trunk and/or limbs

        Exclusion Criteria:

          -  Subjects with scars, moles, tattoos, sunburn or other blemishes in test areas

          -  Systemic treatment with immunosuppressants, immunomodulators or corticosteroids within
             2 weeks prior to dosing

          -  Topical treatment with corticosteroids, antibiotics and/or immunomodulators within 4
             days prior to dosing

          -  Treatment with systemic antihistamines within 24 hours of the first dose
             administration

          -  Treatment with SSRIs within 2 weeks of the first dose administration

          -  Subjects who have received phototherapy within 4 weeks prior to dosing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jim Bush</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance CRU</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance CRU</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRLCRU Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2015</study_first_submitted>
  <study_first_submitted_qc>March 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2015</study_first_posted>
  <last_update_submitted>December 10, 2015</last_update_submitted>
  <last_update_submitted_qc>December 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

